Targeted Protein Degradation in Cancer: PROTACs, New Targets, and Clinical Mechanisms
Biomolecules · 19.02.2026 · 16 (2) · 325
DOI: 10.3390/biom16020325 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Biomolecules, online erschienen am 19.02.2026. Verfasst von Bushra Faryal und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Precision Medicine, University of Campania "Luigi Vanvitelli", 80138 Naples, Italy. Hauptthemen laut MEDLINE: Neoplasms, Antineoplastic Agents. Die Arbeit wurde bisher 25-mal zitiert (Crossref) und nennt 192 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
The onset of proteolysis targeting chimeras (PROTACs) has reshaped the entire context of targeted cancer therapy by offering a novel approach for the selective degradation of disease-causing proteins, overcoming the limitations of traditional occupancy-driven inhibition. This heterobifunctional technology recruits endogenous E3 ubiquitin ligases to mark proteins of interest (POI) for proteosomal degradation via the ubiquitin-proteasome system (UPS). Unlike conventional inhibitors, PROTACs function catalytically and can target previously “undruggable proteins”, such as transcription factors, scaffold proteins, and non-enzymatic regulators, offering potential to overcome acquired resistance and achieve potent efficacy at sub-stoichiometric doses. The review explores the latest innovations in PROTAC design, including E3 ligase selection, linker chemistry, and ligand optimization, while highlighting promising preclinical and clinical candidates against oncogenic drivers, anti-apoptotic factors (BCL-xL), and nuclear hormone receptors. Furthermore, we critically examine key translational challenges, such as pharmacokinetics, off-target effects, and resistance mechanisms, and discuss viable solutions, including dual E3 ligase engagement, novel modalities like AUTACs/ATTECs, LYTACs, and AI-driven design. As the field rapidly evolves from foundational to clinical application, PROTACs are redefining therapeutic possibilities, offering a robust, flexible, and scalable framework for the future of precision oncology.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Precision Medicine, University of Campania "Luigi Vanvitelli", 80138 Naples, Italy.
- Department of Biosciences, COMSATS University Islamabad, Islamabad 45550, Pakistan.
- The Department of Pharmaceutical and Chemistry, Alfraganus University, Tashkent 100190, Uzbekistan.
- Kimyo International University in Tashkent, Shota Rustaveli str. 156, Tashkent 100121, Uzbekistan.
- Low Dimensional Materials Research Center, Khazar University, Baku AZ1096, Azerbaijan.
ORCID-Profile: Bushra Faryal, Zain Ul Abideen, Muhammad Irfan, Ghulam Abbas Ashraf
Zitieren
APA
Faryal, B., Ul Abideen, Z., Irfan, M., Ahmed, H., Jalilov, F., Abduraximova, L., & Ashraf, G. A. (2026). Targeted Protein Degradation in Cancer: PROTACs, New Targets, and Clinical Mechanisms. Biomolecules, 16(2), 325. https://doi.org/10.3390/biom16020325
Vancouver
Faryal B, Ul Abideen Z, Irfan M, Ahmed H, Jalilov F, Abduraximova L, et al. Targeted Protein Degradation in Cancer: PROTACs, New Targets, and Clinical Mechanisms. Biomolecules. 2026;16(2):325. doi:10.3390/biom16020325
BibTeX
@article{Faryal2026,
author = {Faryal, Bushra and Ul Abideen, Zain and Irfan, Muhammad and Ahmed, Haseeb and Jalilov, Fazliddin and Abduraximova, Lola and Ashraf, Ghulam Abbas},
title = {Targeted Protein Degradation in Cancer: PROTACs, New Targets, and Clinical Mechanisms},
journal = {Biomolecules},
year = {2026},
volume = {16},
number = {2},
pages = {325},
doi = {10.3390/biom16020325}
}
EUVIMED